LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, announced that the underwriters for its
public offering of 1,000,000 shares of its common stock at $190.00 per
share have elected to exercise in full their option to purchase up to an
additional 150,000 shares of common stock at the public offering price,
less the underwriting discount. The closing for the additional purchase
of 150,000 shares is expected to take place concurrently with the
closing for the initial purchase of 1,000,000 shares on January 27,
2015, subject to customary closing conditions.
BofA Merrill Lynch and J.P. Morgan are acting as lead book-running
managers and Citigroup is acting as joint book-running manager for the
offering. Leerink LLC and Cowen and Company, LLC are acting as
co-managers for the offering.
The offering is being made pursuant to an automatically effective shelf
registration statement filed with the Securities and Exchange Commission
on January 20, 2015. A prospectus supplement describing the terms of the
offering has been filed with the SEC and forms a part of the effective
registration statement and is available on the SEC’s web site at www.sec.gov.
Copies of the prospectus supplement and the accompanying prospectus
relating to the offering may be obtained by contacting BofA Merrill
Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department,
email: dg.prospectus_requests@baml.com;
J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, phone: (866)
803-9204; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, phone: (800) 831-9146.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
Contact: